"record_id","drug","biomarker","biomarker_relations","biomarker_description","disease","curator","source","source_id"
"BiomarkerKG594659457","ABACAVIR","HLA-B",NA,"HLA-B POLYMORPHISM NA","AIDS","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1498962895","ABEMACICLIB","ESR, ERBB2","AND","ESR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE","(HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1064188334","AFATINIB","EGFR",NA,"EGFR MUTATION NA","LUNG CANCER","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1932775397","ALECTINIB","ALK",NA,"ALK PROTEIN EXPRESSION NA","NON-SMALL CELL LUNG CANCER THAT HAS SPREAD TO OTHER PARTS OF THE BODY","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-955586545","ALPELISIB","ESR, ERBB2, PIK3CA","AND,AND","ESR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE AND PIK3CA MUTATION POSITIVE","ADVANCED OR METASTATIC BREAST CANCER","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1386474016","AMIFAMPRIDINE","NAT2",NA,"NAT2 POLYMORPHISM NA","LAMBERT-EATON MYASTHENIA SYNDROME IN ADULTS","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1029442076","AMIFAMPRIDINE PHOSPHATE","NAT2",NA,"NAT2 POLYMORPHISM NA","LAMBERT-EATON SYNDROME","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1233009142","AMITRIPTYLINE","CYP2D6",NA,"CYP2D6 POLYMORPHISM NA","DEPRESSION","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG979588562","AMOXAPINE","CYP2D6",NA,"CYP2D6 POLYMORPHISM NA","DEPRESSION","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG2008815520","AMPHETAMINE","CYP2D7",NA,"CYP2D7 POLYMORPHISM NA","ATTENTION DEFICIT HYPERACTIVITY DISORDER,OBESITY","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG445115987","ARFORMOTEROL","UGT1A1, CYP2D6","AND/OR","UGT1A1 POLYMORPHISM POSITIVE AND/OR CYP2D6 POLYMORPHISM POSITIVE","CHRONIC OBSTRUCTIVE PULMONARY DISEASE","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-493957746","ARIPIPRAZOLE   LAUROXIL","CYP2D6",NA,"CYP2D6 POLYMORPHISM NA","SCHIZOPHRENIA AND BIPOLAR DISORDER,MAJOR DEPRESSION,TOURETTE'S DISEASE OR AUTISM","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1476585244","ARSENIC TRIOXIDE","PML-RARA",NA,"PML-RARA TRANSLOCATION NA","BLOOD AND BONE MARROW CANCERS","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1745727063","ARTICAINE, EPINEPHRINE","G6PD",NA,"G6PD PROTEIN EXPRESSION NA","ANESTHESIOLOGY,BEFORE DENTAL CARE TO NUMB THE AREA","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1850603683","ATEZOLIZUMAB","CD274",NA,"CD274 PROTEIN EXPRESSION NA","BREAST BLADDER AND URINARY TRACT CANCERS, NON-SMALL CELL LUNG CANCER.","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG875467658","ATEZOLIZUMAB","CD274, Gene Signature
(T-effector)","AND","CD274 PROTEIN EXPRESSION POSITIVE AND GENE SIGNATURE
(T-EFFECTOR) OTHERS POSITIVE","METASTATIC CHEMOTHERAPY-NAIVE NON-SQUAMOUS NSCLC","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1616970176","ATEZOLIZUMAB","CD274, EGFR, ALK","AND, AND","CD274 PROTEIN EXPRESSION POSITIVE AND EGFR MUTATION NEGATIVE AND ALK MUTATION NEGATIVE","NON-SMALL CELL LUNG CANCER.","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-292801829","ATOMOXETINE","CYP2D6",NA,"CYP2D6 POLYMORPHISM NA","HYPERACTIVE ATTENTION DEFICIT","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG719702881","AVATROMBOPAG","F2, F5, PROC, PROS1, SERPINC1, CYP2C9","OR, OR, OR, OR, OR","F2 POLYMORPHISM NEGATIVE OR F5 POLYMORPHISM NEGATIVE OR PROC POLYMORPHISM NEGATIVE OR PROS1 POLYMORPHISM NEGATIVE OR SERPINC1 POLYMORPHISM NEGATIVE OR CYP2C9 POLYMORPHISM NEGATIVE","THROMBOTIC","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1188758294","AVELUMAB","CD274",NA,"CD274 PROTEIN EXPRESSION NA","MERCKLE CELL CARCINOMA","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1048595055","AZATHIOPRINE","TPMT, NUDT15","AND/OR","TPMT POLYMORPHISM NEGATIVE AND/OR NUDT15 POLYMORPHISM NEGATIVE","AUTOIMMUNE DISEASES","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG2059480590","BELINOSTAT","UGT1A1",NA,"UGT1A1 POLYMORPHISM NA","T CELL LYMPHOMA","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG736314554","BINIMETINIB","BRAF",NA,"BRAF MUTATION NA","MELANOMA","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-378943012","BOCEPREVIR","IFNL3
",NA,"IFNL3 PROTEIN EXPRESSION NA","HEPATITIS C INFECTION","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-771556728","BRENTUXIMAB VEDOTIN","ALK",NA,"ALK MUTATION NA","CLASSICAL HODGKIN LYMPHOMA,ANAPLASTIC LARGE CELL LYMPHOMA","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1173989673","BRENTUXIMAB VEDOTIN","TNFRSF8",NA,"TNFRSF8 PROTEIN EXPRESSION NA","CLASSICAL HODGKIN LYMPHOMA,ANAPLASTIC LARGE CELL LYMPHOMA","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG829815143","BREXPIPRAZOLE","CYP2D6",NA,"CYP2D6 POLYMORPHISM NA","SCHIZOPHRENIA,SEVERE DEPRESSION,ALZHEIMER'S DISEASE","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1437695799","BRIGATINIB","ALK",NA,"ALK MUTATION NA","NON-SMALL CELL LUNG CANCER THAT HAS SPREAD TO OTHER PARTS OF THE BODY","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG282615554","BRIVARACETAM","CYP2C19",NA,"CYP2C19 POLYMORPHISM NA","EPILEPSY","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG816316872","CABOZANTINIB","RET",NA,"RET GENETIC OTHERS NA","NON-SMALL-CELL LUNG CANCER","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1533469514","CAPECITABINE","DPYD",NA,"DPYD MUTATION NA","COLORECTAL CANCER,REAST CANCER","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG205847830","CARBAMAZEPINE","HLA-B, HLA-A","AND/OR","HLA-B POLYMORPHISM NEGATIVE AND/OR HLA-A POLYMORPHISM NEGATIVE","BRIVARACETAM,EPILEPSY,ANTICONVULSANTS","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG541509081","CARGLUMIC ACID","NAGS",NA,"NAGS PROTEIN EXPRESSION NA","INBORN ERRORS OF METABOLISM,HIGH AMMONIA LEVELS","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1069940068","CARIPRAZINE","CYP2D6",NA,"CYP2D6 POLYMORPHISM NA","SCHIZOPHRENIA,BIPOLAR I DISORDER","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1900108140","CARISOPRODOL","CYP2C19",NA,"CYP2C19 POLYMORPHISM NA","SKELETAL MUSCLE DISEAS","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1557071629","CARVEDILOL","CYP2D6",NA,"CYP2D6 POLYMORPHISM NA","HEART FAILURE,HIGH BLOOD PRESSURE,HEART DISEASE","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG900270885","CELECOXIB","CYP2C9",NA,"CYP2C9 POLYMORPHISM NA","ARTHRITIS, ANKYLOSIS AND MENSTRUAL PAIN,RHEUMATOID ARTHRITIS","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG570155103","CEFTRIAXONE","G6PD",NA,"G6PD POLYMORPHISM NA","TREAT OR PREVENT BACTERIAL INFECTIONS","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-413895656","CERITINIB","ALK",NA,"ALK MUTATION NA","LUNG CANCER","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-2121880163","CERLIPONASE ALFA","TPP1",NA,"TPP1 MUTATION NA","TYPE 2 DISEASE OF CEROID LIPOFUSCINOSIS (CLN2)","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1928793512","CETUXIMAB","RAS",NA,"RAS MUTATION NA","CANCER OF THE HEAD AND NECK","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1667727299","CRIZANLIZUMAB","HBB",NA,"HBB MUTATION NA","PEOPLE WITH SICKLE CELL DISEASE","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1839732767","CRIZOTINIB","ROS1",NA,"ROS1 GENE FUSION NA","LUNG CANCER","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1229781644","DABRAFENIB","RAS",NA,"RAS MUTATION NA","SKIN CANCER (MELANOMA)","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-210842937","DENILEUKIN DIFTITOX","IL2RA
",NA,"IL2RA PROTEIN EXPRESSION NA","LEUKEMIA","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG779147928","EFAVIRENZ","CYP2B6",NA,"CYP2B6 POLYMORPHISM NA","HIV INFECTION","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1440571084","ELAGOLIX","SLCO1B1",NA,"SLCO1B1 PROTEIN EXPRESSION NA","MODERATE TO SEVERE PAIN CAUSED BY ENDOMETRIOSIS.","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1362059301","ENASIDENIB","IDH2",NA,"IDH2 MUTATION NA","ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WITH AN IDH2 MUTATION.","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1738472582","ENFORTUMAB VEDOTIN-EJFV","NECTIN4",NA,"NECTIN4 PROTEIN EXPRESSION NA","ADVANCED UROTHELIAL CARCINOMA, BLADDER CANCER","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-622383070","ENTRECTINIB","NTRK",NA,"NTRK GENE FUSION NA","SOLID TUMOR","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-239734061","ERDAFITINIB","FGFR",NA,"FGFR MUTATION & GENE FUSION NA","UROTHELIAL CARCINOMA","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1869766997","ESCITALOPRAM","CYP2C19",NA,"CYP2C19 POLYMORPHISM NA","DEPRESSION","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-978387120","ESTRADIOL, PROGESTERONE","SERPINC1",NA,"SERPINC1 PROTEIN OVEREXPRESSION NA","VASOMOTOR DISEASE","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-998821726","ETEPLIRSEN","DMD",NA,"DMD MUTATION NA","DUCHENNE MUSCULAR DYSTROPHY","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG363506879","FLUOROURACIL","DPYD",NA,"DPYD MUTATION NA","SKIN CANCER","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-23249570","GILTERITINIB","FLT3",NA,"FLT3 MUTATION NA","MYELOMATOSIS","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1859447834","IMATINIB","KIT, FIP1L1-PDGFRA","AND","KIT MUTATION NEGATIVE AND FIP1L1-PDGFRA GENE FUSION POSITIVE","AGGRESSIVE SYSTEMIC MASTOCYTOSIS","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1151651722","IMATINIB","PDGFRB",NA,"PDGFRB TRANSLOCATION NA","MYELODYSPLASTIC","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1147713356","IMATINIB","FIP1L1-PDGFRA",NA,"FIP1L1-PDGFRA GENE FUSION NA","HYPEREOSINOPHILIC SYNDROME (HES) AND","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG166414512","INDACATEROL","UGT1A1",NA,"UGT1A1 POLYMORPHISM NA","ASTHMA","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-539500812","INOTERSEN","TTR",NA,"TTR PROTEIN EXPRESSION NA","FAP(FAMILIAL AMYLOID POLYNEUROPATHY)","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-848100356","IPILIMUMAB","HLA-A",NA,"HLA-A POLYMORPHISM NA","MELANOMA","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1476229835","ISOSORBIDE DINITRATE","CYB5R",NA,"CYB5R PROTEIN EXPRESSION NA","ANGINA","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG637500005","IVOSIDENIB","IDH1",NA,"IDH1 MUTATION POSITIVE","LEUKEMIA","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-726641820","LAPATINIB","HLA-DQA1",NA,"HLA-DQA1 POLYMORPHISM POSITIVE","BREAST CANCER","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG496745715","LAPATINIB","HLA-DRB1",NA,"HLA-DRB1 POLYMORPHISM POSITIVE","BREAST CANCER","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG453634129","LAROTRECTINIB","NTRK",NA,"NTRK GENE FUSION POSITIVE","ABNORMAL NTRK GENE CAUSES CERTAIN TUMORS","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG679917283","MIDOSTAURIN","NPM1",NA,"NPM1 MUTATION POSITIVE","ACUTE MYELOID LEUKEMIA,CERTAIN RARE BLOOD DISORDERS, INCLUDING SYSTEMIC MASTOCYTOSIS WITH MAST CELL LEUKEMIA OR OTHER CANCERS AFFECTING THE BLOOD,BONE MARROW, OR LYMPHATIC TISSUE.","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-49333377","MIDOSTAURIN","KIT",NA,"KIT MUTATION POSITIVE","ACUTE MYELOID LEUKEMIA,CERTAIN RARE BLOOD DISORDERS, INCLUDING SYSTEMIC MASTOCYTOSIS WITH MAST CELL LEUKEMIA OR OTHER CANCERS AFFECTING THE BLOOD,BONE MARROW, OR LYMPHATIC TISSUE.","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1030127933","MIGALASTAT","GLA",NA,"GLA MUTATION POSITIVE","FABRY DISEASE","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-280478680","MIVACURIUM","BCHE",NA,"BCHE POLYMORPHISM POSITIVE","CALM MUSCLES DURING SURGERY,CALM MUSCLES WHILE ON A BREATHING MACHINE","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG2104942858","MYCOPHENOLIC ACID","HPRT1",NA,"HPRT1 PROTEIN EXPRESSION POSITIVE","RGAN REJECTION AFTER A KIDNEY TRANSPLANT","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1086936591","NUSINERSEN","SMN2",NA,"SMN2 PROTEIN EXPRESSION POSITIVE","SPINAL MUSCULAR ATROPHY","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-558455940","OBINUTUZUMAB","MS4A1",NA,"MS4A1 PROTEIN EXPRESSION POSITIVE","LEUKEMIA，LYMPHOMA","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG489011798","OLAPARIB","BRCA",NA,"BRCA MUTATION POSITIVE","OVARIAN CANCER, FALLOPIAN TUBE CANCER, OR PERITONEAL CANCER IN WOMEN WITH A CERTAIN ABNORMAL INHERITED GENE，HER2-NEGATIVE BREAST CANCER，CANCER HAS A SPECIFIC GENETIC MARKER (AN ABNORMAL ""BRCA"" GENE)","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1388758583","OLARATUMAB","PDGFRA",NA,"PDGFRA PROTEIN SILENCING POSITIVE","SOFT TISSUE SARCOMA","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1323391694","PARATHYROID HORMONE","CASR",NA,"CASR MUTATION POSITIVE","CONTROL LOW BLOOD CALCIUM LEVELS IN PEOPLE WHO HAVE LOW BLOOD PARATHYROID HORMONE LEVELS","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG794218917","PEGINTERFERON ALFA-2B","IFNL3",NA,"IFNL3 PROTEIN EXPRESSION POSITIVE","CHRONIC HEPATITIS","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1790679122","PRASUGREL","CYP3A5",NA,"CYP3A5 PROTEIN EXPRESSION POSITIVE","ATHEROSCLEROSIS","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG149207443","RUCAPARIB","CYP1A2",NA,"CYP1A2 PROTEIN EXPRESSION POSITIVE","OVARIAN CANCER","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1053117702","USTEKINUMAB","IL12A, IL12B, IL23A","AND/OR, AND/OR","IL12A MUTATION POSITIVE AND/OR IL12B MUTATION POSITIVE AND/OR IL23A MUTATION POSITIVE","COLITIS (UC)","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1944943287","VALPROIC ACID","POLG",NA,"POLG MUTATION POSITIVE","EPILEPSY","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1127858044","VENETOCLAX","TP53",NA,"TP53 MUTATION POSITIVE","LEUCOCYTHEMIA","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-1962047831","VENETOCLAX","IGH",NA,"IGH TRANSLOCATION POSITIVE","LEUCOCYTHEMIA","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-357946721","WARFARIN","VKORC1",NA,"VKORC1 POLYMORPHISM POSITIVE","VENOUS THROMBOEMBOLIC DISEASE (VTE)","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG2028368899","WARFARIN","PROS1",NA,"PROS1 MUTATION POSITIVE","VENOUS THROMBOEMBOLIC DISEASE (VTE)","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG313586149","WARFARIN","PROC",NA,"PROC MUTATION POSITIVE","VENOUS THROMBOEMBOLIC DISEASE (VTE)","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG-2104469395","SODIUM   PHENYLBUTYRATE","ASS1, CPS1, OTC","OR,OR","ASS1 MUTATION POSITIVE OR CPS1 MUTATION POSITIVE OR OTC MUTATION POSITIVE","ENZYME DEFICIENCY","Ben","FDA","https://www.fda.gov/media/124784/download"
"BiomarkerKG1514699161","NIVOLUMAB, IPILIMUMAB","ESR1, PGR, ERBB2","AND, AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","ALV","clinicaltrials.gov","NCT03818685"
"BiomarkerKG-1435553749","IMIPRAMINE","ESR1, PGR, ERBB2","AND, AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","ALV","clinicaltrials.gov","NCT03122444"
"BiomarkerKG-1899271805","PALBOCICLIB, LETROZOLE","ERBB2, PGR, ESR1","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","ALV","clinicaltrials.gov","NCT04047758"
"BiomarkerKG809776760","PYROTINIB, ETOPOSIDE","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT03923179"
"BiomarkerKG-1915782920","DOCETAXEL, RITONAVIR","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","RECURRENT BREAST CANCER","ALV","clinicaltrials.gov","NCT03890744"
"BiomarkerKG-156769428","DURVALUMAB, TRASTUZUMAB, PERTUZUMAB","ERBB2, PGR, ESR1","AND, AND","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER (I-II)","ALV","clinicaltrials.gov","NCT03820141"
"BiomarkerKG-1013990068","PACLITAXEL, TRASTUZUMAB, CARBOPLATIN, PERTUZUMAB","ERBB2, PGR, ESR1","AND, AND","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER (STAGE II-III)","ALV","clinicaltrials.gov","NCT03820063"
"BiomarkerKG-447481596","ONAPRISTONE","ESR1, PGR, ERBB2, Ki67","AND, AND, AND","ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","BREAST CANCER (I-II)","ALV","clinicaltrials.gov","NCT04142892"
"BiomarkerKG-859329038","PEMBROLIZUMAB, PEGYLATED LIPOSOMAL DOXORUBICIN","ESR1, ERBB2","AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER (III-IV)","ALV","clinicaltrials.gov","NCT03591276"
"BiomarkerKG687053448","PYROTINIB, CAPECITABINE","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","BREAST CANCER","ALV","clinicaltrials.gov","NCT03923166"
"BiomarkerKG-889764113","PEMBROLIZUMAB, PACLITAXEL","ESR1, ERBB2, Ki67","AND, AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC LUMINAL B BREAST CANCER","ALV","clinicaltrials.gov","NCT03841747"
"BiomarkerKG-103720969","PYROTINIB, ALBUMIN-BOUND PACLITAXEL, TRASTUZUMAB, EPRIRUBICIN, CYCLOPHOSPHAMIDE","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION &AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","BREAST CANCER (I-III)","ALV","clinicaltrials.gov","NCT04066790"
"BiomarkerKG-1504794440","PYROTINIB","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","ALV","clinicaltrials.gov","NCT03980054"
"BiomarkerKG1827935371","LETROZOLE, PYROTINIB, SHR6390","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT03772353"
"BiomarkerKG1686449390","CAPECITABINE","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","NON-METASTATIC INVASIVE BREAST CANCER","ALV","clinicaltrials.gov","NCT03958721"
"BiomarkerKG-435072881","DOCETAXEL, CYCLOPHOSPHAMIDE, TRASTUZUMAB","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","BREAST NEOPLASMS","ALV","clinicaltrials.gov","NCT03705429"
"BiomarkerKG1596444665","SAR439859","ERBB2, ESR1","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT03816839"
"BiomarkerKG-316459000","IPATASERTIB, PALBOCICLIB, FULVESTRANT","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT04060862"
"BiomarkerKG1503939067","ERIBULIN, BALIXAFORTIDE","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","LOCALLY RECURRENT OR METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT03786094"
"BiomarkerKG-2032842044","VENETOCLAX, PALBOCICLIB, LETROZOLE","ESR1, Bcl2, ERBB2","AND, AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND BCL2 PROTEIN EXPRESSION POSITIVE AND/OR ERBB2 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT03900884"
"BiomarkerKG276424285","ATEZOLIZUMAB, DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL, PERTUZUMAB, TRASTUZUMAB EMTANSINE","ERBB2, ESR1, PGR, PDL1","AND, AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","BREAST CANCER (I-III)","ALV","clinicaltrials.gov","NCT03726879"
"BiomarkerKG1623818552","FS-1502","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT03944499"
"BiomarkerKG-627703212","IPI-549, ATEZOLIZUMAB, NAB-PACLITAXEL","ERBB2, ESR1, PGR, PDL1","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ALV","clinicaltrials.gov","NCT03961698"
"BiomarkerKG-1795461556","ALL-TRANS RETINOIC ACID, ANASTROZOLE","ESR1, ERBB2, Ki67","AND, AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","BREAST NEOPLASM","ALV","clinicaltrials.gov","NCT04113863"
"BiomarkerKG1649159632","PYROTINIB, CAPECITABINE","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT04001621"
"BiomarkerKG-1239420556","NIVOLUMAB, IPILIMUMAB, BICALUTAMIDE","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BREAST CANCER","ALV","clinicaltrials.gov","NCT03650894"
"BiomarkerKG-2135616330","NAB-PACLITAXEL, CARBOPLATIN, CAPECITABINE","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","ADVANCED TRIPLE-NEGATIVE BREAST CANCER","ALV","clinicaltrials.gov","NCT04159142"
"BiomarkerKG2061889424","RIBOCICLIB, TRASTUZUMAB, LETROZOLE","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION AND AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","POSTMENOPAUSAL ADVANCED METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT03913234"
"BiomarkerKG905609745","LETROZOLE, PALBOCICLIB","ERBB2, ESR1, PGR, Ki67","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE","BREAST CANCER (II-IIIB)","ALV","clinicaltrials.gov","NCT03819010"
"BiomarkerKG345427327","PYROTINIB, TRASTUZUMAB, DOCETAXEL, CARBOPLATIN","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","EARLY STAGE OR LOCALLY ADVANCED BREAST CANCER","ALV","clinicaltrials.gov","NCT03756064"
"BiomarkerKG702885081","COPANLISIB, TRASTUZUMAB EMTANSINE","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","UNRESECTABLE LOCALLY ADVANCED OR METASTATIC  BREAST CANCER","ALV","clinicaltrials.gov","NCT04042051"
"BiomarkerKG-1430355371","ATEZOLIZUMAB, CAPECITABINE","ERBB2, ESR1, PGR, PDL1","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","TRIPLE NEGATIVE BREAST CANCER","ALV","clinicaltrials.gov","NCT03756298"
"BiomarkerKG-1139236655","DURVALUMAB, OLAPARIB, FULVESTRANT","ERBB2, ESR1, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FAND2, FANCL, MRE11A, NBN, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, AKT1, FGFR1, FGFR2, FGFR3, PIK3CA","AND, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION/MUTATION POSITIVE AND/OR ATM MUTATION POSITIVE AND/OR BARD1 MUTATION POSITIVE AND/OR BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND/OR BRIP1 MUTATION POSITIVE AND/OR CDK12 MUTATION POSITIVE AND/OR CHEK1 MUTATION POSITIVE AND/OR CHEK2 MUTATION POSITIVE AND/OR FANCA MUTATION POSITIVE AND/OR FAND2 MUTATION POSITIVE AND/OR FANCL MUTATION POSITIVE AND/OR MRE11A MUTATION POSITIVE AND/OR NBN MUTATION POSITIVE AND/OR PALB2 MUTATION POSITIVE AND/OR PPP2R2A MUTATION POSITIVE AND/OR RAD51B MUTATION POSITIVE AND/OR RAD51C MUTATION POSITIVE AND/OR RAD51D MUTATION POSITIVE AND/OR RAD54L MUTATION POSITIVE AND/OR AKT1 MUTATION POSITIVE AND/OR FGFR1 MUTATION POSITIVE AND/OR FGFR2 MUTATION POSITIVE AND/OR FGFR3 MUTATION POSITIVE AND/OR PIK3CA MUTATION POSITIVE","METASTATIC OR LOCALLY ADVANCED BREAST CANCER","ALV","clinicaltrials.gov","NCT04053322"
"BiomarkerKG1505390240","PYROTINIB MALEATE, DOCETAXEL","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT03876587"
"BiomarkerKG-2093307115","TESETAXEL, CAPECITABINE","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT03858972"
"BiomarkerKG729598124","PYROTINIB MALEATE, ALBUMIN PACLITAXEL, TRASTUZUMAB","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","EARLY OR LOCALLY ADVANCED BREAST CANCER (II-III)","ALV","clinicaltrials.gov","NCT04152057"
"BiomarkerKG-1616092040","OLAPARIB","ERBB2, ESR1, PGR, BRCA1, BRCA2","AND/OR, AND/OR, AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","METASTATIC MALIGNANT NEOPLASM IN THE CHEST WALL","ALV","clinicaltrials.gov","NCT03955640"
"BiomarkerKG-226063560","PALBOCICLIB, LETROZOLE","ERBB2, ESR1","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER STAGE IV","ALV","clinicaltrials.gov","NCT03870919"
"BiomarkerKG-601099740","PYROTINIB, TRASTUZUMAB, DOCETAXEL","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT03863223"
"BiomarkerKG-274333150","SACITUZUMAB GOVITECAN","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC OR LOCALLY RECURRENT INOPERABLE BREAST CANCER","ALV","clinicaltrials.gov","NCT03901339"
"BiomarkerKG921194961","NERATINIB, PACLITAXEL, CARBOPLATIN","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","EARLY STAGE TRIPLE-NEGATIVE BREAST CANCER","ALV","clinicaltrials.gov","NCT03812393"
"BiomarkerKG-1540813963","PALBOCICLIB, BOSUTINIB, FULVESTRANT","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCOREGIONALLY RECURRENT OR METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT03854903"
"BiomarkerKG1068866669","LERONLIMAB, CARBOPLATIN","ERBB2, CCR5, ESR1, PGR","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND CCR5 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER","ALV","clinicaltrials.gov","NCT03838367"
"BiomarkerKG-1471164927","LY3023414, PREXASERTIB","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","ALV","clinicaltrials.gov","NCT04032080"
"BiomarkerKG-57313394","NAB-PACLITAXEL, CARBOPLATIN, EPIRUBICIN, CYCLOPHOSPHAMIDE","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","ALV","clinicaltrials.gov","NCT04067102"
"BiomarkerKG-617297347","ABEMACICLIB, COPANLISIB, COPANLISIB HYDROCHLORIDE, FULVESTRANT","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT03939897"
"BiomarkerKG-891847787","PYROTINIB MALEATE, ALBUMIN PACLITAXEL, TRASTUZUMAB, EPIRUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","EARLY OR LOCALLY ADVANCED BREAST CANCER (II-III)","ALV","clinicaltrials.gov","NCT04152057"
"BiomarkerKG1568508684","PEMBROLIZUMAB, LENVATINIB","ERBB2, ESR1, PGR, LDH","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND LDH PROTEIN EXPRESSION POSITIVE","ADVANCED TRIPLE NEGATIVE BREAST CANCER","ALV","clinicaltrials.gov","NCT03797326"
"BiomarkerKG551843489","9-ING-41, GEMCITABINE, DOXORUBICIN, LOMUSTINE, CARBOPLATIN, NAB PACLITAXEL, PACLITAXEL, IRINOTECAN","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT03678883"
"BiomarkerKG1477271139","NAPTUMOMAB ESTAFENATOX, DURVALUMAB","ERBB2, ESR1, PGR, 5T4","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND 5T4 PROTEIN EXPRESSION POSITIVE/NEGATIVE","ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ALV","clinicaltrials.gov","NCT03983954"
"BiomarkerKG285317920","NAPTUMOMAB ESTAFENATOX, DURVALUMAB","ERBB2, ESR1, 5T4","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND 5T4 PROTEIN EXPRESSION POSITIVE/NEGATIVE","ADVANCED OR METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT03983954"
"BiomarkerKG-482905584","REBASTINIB, CARBOPLATIN","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ALV","clinicaltrials.gov","NCT03717415"
"BiomarkerKG-1661914186","PYROTINIB, SHR6390, LETROZOLE","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT04095390"
"BiomarkerKG-1814161762","PYROTINIB, SHR6390, CAPECITABINE","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT04095390"
"BiomarkerKG-437004938","ATEZOLIZUMAB, IPATASERTIB, PACLITAXEL","ERBB2, ESR1, PGR, PDL1, BRCA1, BRCA2","AND, AND, AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ALV","clinicaltrials.gov","NCT04177108"
"BiomarkerKG-1110084195","NIVOLUMAB, ABEMACICLIB, ANASTROZOLE, PALBOCICLIB","ERBB2, ESR1","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","ALV","clinicaltrials.gov","NCT04075604"
"BiomarkerKG1364396589","NIVOLUMAB, DOXORUBICIN","ERBB2, ESR1, PGR, Ki67","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","RESECTABLE PRIMARY TRIPLE NEGATIVE BREAST CANCER (STAGE I-III)","ALV","clinicaltrials.gov","NCT03815890"
"BiomarkerKG-1448510916","NIVOLUMAB, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","INFLAMMATORY TRIPLE NEGATIVE BREAST CANCER","ALV","clinicaltrials.gov","NCT03742986"
"BiomarkerKG-2022083316","NIVOLUMAB, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE, TRASTUZUMAB, PERTUZUMAB","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","INFLAMMATORY BREAST CANCER","ALV","clinicaltrials.gov","NCT03742986"
"BiomarkerKG356324322","ABEMACICLIB, DURVALUMAB, AROMATASE INHIBITOR","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED BREAST CANCER (II-III)","ALV","clinicaltrials.gov","NCT04088032"
"BiomarkerKG-104675348","PACLITAXEL, CARBOPLATIN, CYCLOPHOSPHAMIDE","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE INVASIVE BREAST CANCER","ALV","clinicaltrials.gov","NCT03858322"
"BiomarkerKG-1384231495","RIBOCICLIB, ENDOCRINE THERAPY","ERBB2, ESR1","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","VISCERAL METASTATIC BREAST CANCER","ALV","clinicaltrials.gov","NCT03905343"
"BiomarkerKG34334946","ENTINOSTAT, CAPECITABINE","ESR1, PGR, ERBB2","OR, AND","ESR1 PROTEIN EXPRESSION POSITVE/NEGATIVE OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER, BREAST CANCER","TVV","clinicaltrials.gov","NCT03473639"
"BiomarkerKG1946912801","TALAZOPARIB, SACITUZUMAB GOVITECAN","ESR1, PGR, ERBB2","AND, AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE-NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT04039230"
"BiomarkerKG-1577117464","TRASTUZUMAB, GDC-0084","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITVE","ERBB2-POSITIVE BREAST CANCER BRAIN METASTASES","TVV","clinicaltrials.gov","NCT03765983"
"BiomarkerKG-2085566364","ASPIRIN, TAMOXIFEN, DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL","ESR1, ERBB2","AND","ESR1 PROTEIN EXPRESSION POSITVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER (STAGE I-III)","TVV","clinicaltrials.gov","NCT04038489"
"BiomarkerKG-1363681835","NAB-PACLITAXEL","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","PRIMARY INVASIVE BREAST CANCER AND CLINICAL STAGE I - III, FIRST OPTION Ⅳ","TVV","clinicaltrials.gov","NCT03959397"
"BiomarkerKG-1494023734","NIVOLUMAB, IPILIMUMAB","ERBB2, ER, PGR","AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND/OR ER PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT03789110"
"BiomarkerKG1251372237","SIMVASTATIN","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","BREAST CANCER STAGE (STAGE IV)","TVV","clinicaltrials.gov","NCT03324425"
"BiomarkerKG-153611909","PEMBROLIZUMAB, TAMOXIFEN","ESR1, ERBB2, PGR","AND, AND/OR","ESR1 MUTATION POSITVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","BREAST CANCER FEMALE","TVV","clinicaltrials.gov","NCT03879174"
"BiomarkerKG351003137","APATINIB, PACLITAXEL, CISPLATIN","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER","TVV","clinicaltrials.gov","NCT03982485"
"BiomarkerKG-1579678160","PALBOCICLIB","ERBB2, ESR1","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER STAGE (STAGE II-III)","TVV","clinicaltrials.gov","NCT03609047"
"BiomarkerKG118603023","DOCETAXEL, CARBOPLATIN, TRASTUZUMAB, PERTUZUMAB, EPIRUBICIN, CYCLOPHOSPHAMIDE, ATEZOLIZUMAB, TRASTUZUMAB EMTANSINE","ERBB2, ESR1, PGR, PDl1","AND, AND, AND","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE AND PDL1 PROTEIN EXPRESSION POSITVE","EARLY-STAGE BREAST CANCER","TVV","clinicaltrials.gov","NCT03894007"
"BiomarkerKG1189074014","OLAPARIB, VORINOSTAT","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER METASTATIC, BREAST CANCER","TVV","clinicaltrials.gov","NCT03742245"
"BiomarkerKG-388096993","NIRAPARIB, TRASTUZUMAB","ERBB2, ESR1, PR","AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION NEGATIVIE/POSITIVE AND/OR PR PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER, ERBB2 POSITIVE BREAST CARCINOMA","TVV","clinicaltrials.gov","NCT03368729"
"BiomarkerKG1874182044","DOCETAXEL, CARBOPLATIN, TRASTUZUMAB, PERTUZUMAB","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITVE","INVASIVE BREAST CARCINOMA","TVV","clinicaltrials.gov","NCT04094896"
"BiomarkerKG2087957969","NIVOLUMAB, PACLITAXEL, ANTHRACYCLINE, CYCLOPHOSPHAMIDE, ENDOCRINE THERAPY","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","BREAST CANCER","TVV","clinicaltrials.gov","NCT04109066"
"BiomarkerKG1644765431","RUCAPARIB","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TNBC BREAST CANCER  (STAGE I-III)","TVV","clinicaltrials.gov","NCT03911453"
"BiomarkerKG-262451806","PALBOCICLIB, LETROZOLE, TRASTUZUMAB, PERTUZUMAB","ESR1, ERBB2","AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","BREAST CANCER","TVV","clinicaltrials.gov","NCT03644186"
"BiomarkerKG-1083648118","ERIBULIN","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT03637868"
"BiomarkerKG-225817822","RIBOCICLIB, LETROZOLE OR ANASTROZOLE, GOSERELIN","ERBB2, PGR,ESR1","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE","ADVANCED BREAST CANCER","TVV","clinicaltrials.gov","NCT03822468"
"BiomarkerKG-2009160467","IPILIMUMAB, NIVOLUMAB","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TNBC BREAST CANCER","TVV","clinicaltrials.gov","NCT03546686"
"BiomarkerKG-1723002468","PALBOCICLIB, EXEMESTANE, GOSERELIN","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT02917005"
"BiomarkerKG-604627963","RIBOCICLIB, LETROZOLE","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","NON-METASTATIC PRIMARY LUMINAL BREAST CANCER (STAGE II-III)","TVV","clinicaltrials.gov","NCT03283384"
"BiomarkerKG-1030601521","ERIBULIN, NIVOLUMAB","ERBB2, ESR1","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT04061863"
"BiomarkerKG138689674","PEMBROLIZUMAB, TRASTUZUMAB BIOSIMILAR ABP 980, PERTUZUMAB","ERBB2, ESR1, PGR","AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","BREAST CANCER","TVV","clinicaltrials.gov","NCT03988036"
"BiomarkerKG397892956","CFI-400945, DURVALUMAB","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TNBC BREAST CANCER","TVV","clinicaltrials.gov","NCT04176848"
"BiomarkerKG721208190","RIBOCICLIB, LETROZOLE OR ANASTROZOLE, GOSERELIN","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","PREMENOPAUSAL OR PERIMENOPAUSAL LOCALLY ADVANCED OR METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT03839823"
"BiomarkerKG1288315268","CHIDAMIDE, CISPLATIN","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT04192903"
"BiomarkerKG-2056951534","PYROTINIB, FULVESTRANT","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT04034589"
"BiomarkerKG-1897970195","LASOFOXIFENE","ERBB2, ESR1","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT03781063"
"BiomarkerKG996483862","OLAPARIB, TRASTUZUMAB","BRCA1,BRCA2, ERBB2","AND/OR, AND","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","RECURRENT OR METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT03931551"
"BiomarkerKG-1884678499","ABEMACICLIB, FULVESTRANT","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT04031885"
"BiomarkerKG1863117410","PEMBROLIZUMAB","ESR1, PGR","AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","STAGE IV METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT03492918"
"BiomarkerKG289580844","PYROTINIB, VINORELBINE","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT03997539"
"BiomarkerKG-2074888963","PALBOCICLIB, ENDOCRINE THERAPY","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","RECURRENT BREAST CANCER","TVV","clinicaltrials.gov","NCT03820830"
"BiomarkerKG1360761977","DURVALUMAB, ENDOCRINE THERAPY","ERBB2, ESR1","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","TVV","clinicaltrials.gov","NCT03874325"
"BiomarkerKG1586324685","LYNPARZA","BRCA1,BRCA2, ERBB2, ESR1, PGR","AND/OR, AND, AND, AND","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT04041128"
"BiomarkerKG-1645794555","VINORELBINE, APATINIB","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03932526"
"BiomarkerKG-1304175737","ABEMACICLIB, ANASTROZOLE, FULVESTRANT, LETROZOLE, PALBOCICLIB, RIBOCICLIB","ESR1, PGR","AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT04256941"
"BiomarkerKG-1019298398","PACLITAXEL, NAB-PACLITAXEL, ATEZOLIZUMAB","ERBB2, ESR1, PGR, PDL1","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT04148911"
"BiomarkerKG67951044","CARBOPLATIN, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT04083963"
"BiomarkerKG1857107666","NIRAPARIB","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03945721"
"BiomarkerKG735236579","CAMRELIZUMAB, NAB-PACLITAXEL, FAMITINIB","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT04129996"
"BiomarkerKG-800369839","NAB-PACLITAXEL, EPIRUBICIN, CARBOPLATIN","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT04138719"
"BiomarkerKG-835107575","CRIZOTINIB, FULVESTRANT","ERBB2, ESR1","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","ADVANCED BREAST CANCER","TVV","clinicaltrials.gov","NCT03620643"
"BiomarkerKG-293355652","PYROTINIB MALEATE, NAB-PACLITAXEL","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT03919253"
"BiomarkerKG-1189924932","PEMBROLIZUMAB","ERBB2, APOBEC3B, ER","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND APOBEC3B MUTATION POSITIVE AND ER PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT03989089"
"BiomarkerKG-1632658776","PEMBROLIZUMAB, CARBOPLATIN, GEMCITABINE, OLAPARIB","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT04191135"
"BiomarkerKG358990573","PYROTINIB, TRASTUZUMAB, VINORELBINE","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","EARLY STAGE OR LOCALLY ADVANCED BREAST CANCER","TVV","clinicaltrials.gov","NCT03947242"
"BiomarkerKG-1876496357","PYROTINIB, TRASTUZUMAB, DOCETAXEL, CARBOPLATIN","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","EARLY STAGE OR LOCALLY ADVANCED BREAST CANCER","TVV","clinicaltrials.gov","NCT03847818"
"BiomarkerKG-33556113","DOCETAXEL, ATEZOLIZUMAB, TRASTUZUMAB SC, PERTUZUMAB, DOXORUBICIN, CYCLOPHOSPHAMIDE, HERCEPTIN SC","ERBB2, ESR1","AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","LOCALLY ADVANCED","TVV","clinicaltrials.gov","NCT03881878"
"BiomarkerKG-599028211","TUCATINIB, T-DM1","ERBB2, ESR1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT03975647"
"BiomarkerKG1688452319","SPARTALIZUMAB, LAG525, NIR178, CAPMATINIB, MCS110, CANAKINUMAB","ERBB2, ESR1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03742349"
"BiomarkerKG-453264115","CARBOPLATIN, PACLITAXEL","ERBB2, ESR1, PGR, BRCA1, BRCA2","AND, AND, AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03876886"
"BiomarkerKG-1503610555","BERZOSERTIB","ERBB2, ERS1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT04052555"
"BiomarkerKG179888471","OLECLUMAB, DURVALUMAB","ERBB2, ERS1, Ki67, PDL1","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","LUMINAL B BREAST CANCER","TVV","clinicaltrials.gov"," NCT03875573"
"BiomarkerKG1995732573","CARBOPLATIN, IPATASERTIB, PACLITAXEL","ERBB2, ERS1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03853707"
"BiomarkerKG1739611934","PALBOCICLIB, ENDOCRINE THERAPY","ERBB2, ERS1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","ADVANCED BREAST CANCER","TVV","clinicaltrials.gov"," NCT03809988"
"BiomarkerKG-915701665","CAPIVASERTIB, PACLITAXEL","ERBB2, ERS1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03997123"
"BiomarkerKG-689338926","ALPELISIB, ENZALUTAMIDE","ERBB2, ERS1, PGR, AR, PTEN","AND, AND/OR, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND AR PROTEIN EXPRESSION POSITIVE AND PTEN MUTATION POSITIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT03207529"
"BiomarkerKG-975392028","IPATASERTIB, RUCAPARIB","ERBB2, ERS1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT03840200"
"BiomarkerKG2065001521","PERTUZUMAB, TRASTUZUMAB, COPANLISIB","ERBB2, ERS1, PGR, PTEN, PIK3CA","AND, AND, AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PTEN MUTATION POSITIVE AND PIK3CA MUTATION POSITIVE","ADVANCED BREAST CANCER","TVV","clinicaltrials.gov","NCT04108858"
"BiomarkerKG-170542798","PACLITAXEL, TALIMOGENE LAHERPAREPVEC","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC OR LOCOREGIONALLY RECCURENT BREAST CANCER","TVV","clinicaltrials.gov","NCT03554044"
"BiomarkerKG-743019303","TAMOXIFEN, TALIMOGENE LAHERPAREPVEC, LETROZOLE, FULVESTRANT, EXEMESTANE, ANASTROZOLE","ERBB2, ERS1","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE","METASTATIC OR LOCOREGIONALLY RECCURENT BREAST CANCER","TVV","clinicaltrials.gov","NCT03554044"
"BiomarkerKG302277995","COPANLISIB, FULVESTRANT","ERBB2, ERS1, PIK3CA, PTEN","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND PIK3CA MUTATION NEGATIVE/POSITIVE AND PTEN MUTATION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT03803761"
"BiomarkerKG-635888986","AVELUMAB, BINIMETINIB, PF-04518600, UTOMILUMAB","ERBB2, ERS1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","STAGE IV TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03971409"
"BiomarkerKG-544075815","PYROTINIB, TRASTUZUMAB, AROMATASE INHIBITORS","ERBB2, ERS1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","ADVANCED INVASIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT04088110"
"BiomarkerKG-820225238","LEFLUNOMIDE","ERBB2, ERS1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03709446"
"BiomarkerKG-10442632","TESETAXEL, NIVOLUMAB, PEMBROLIZUMAB, ATEZOLIZUMAB","ERBB2, ERS1, PGR, PDL1","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03952325"
"BiomarkerKG-1944338472","TESETAXEL","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT03952325"
"BiomarkerKG-1575067713","TAMOXIFEN","BRCA1, BRCA2, ESR1","AND, AND","BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST DUCTAL CARCINOMA IN SITU","TVV","clinicaltrials.gov","NCT04046159"
"BiomarkerKG-1945881394","CELECOXIB, CYCLOPHOSPHAMIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL, RECOMBINANT INTERFERON ALFA-2B, RINTATOLIMOD","ERBB2, ERS1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","EARLY STAGE TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT04081389"
"BiomarkerKG-1955995515","ATEZOLIZUMAB, PACLITAXEL, PERTUZUMAB, TRASTUZUMAB","ERBB2, ERS1, PGR, PDL1","AND, AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT03199885"
"BiomarkerKG1825741352","CYCLOPHOSPHAMIDE, LYSO-THERMOSENSITIVE LIPOSOMAL DOXORUBICIN","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT03749850"
"BiomarkerKG156569843","ATORVASTATIN","ERBB2, ERS1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","STAGE IIB-III TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03872388"
"BiomarkerKG-179581873","IPILIMUMAB, NIVOLUMAB, TALIMOGENE LAHERPAREPVEC","ERBB2, ERS1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALIZED BREAST CANCER","TVV","clinicaltrials.gov","NCT04185311"
"BiomarkerKG-1062210253","IPILIMUMAB, NIVOLUMAB, TALIMOGENE LAHERPAREPVEC","ERBB2, ERS1","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE","LOCALIZED BREAST CANCER","TVV","clinicaltrials.gov","NCT04185311"
"BiomarkerKG2095042473","PEMBROLIZUMAB, CYCLOPHOSPHAMIDE, GX-I7","ERBB2, ERS1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","REFRACTORY OR RELAPSED TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03752723"
"BiomarkerKG-1855863757","TRASTUZUMAB","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","EARLY BREAST CANCER","TVV","clinicaltrials.gov","NCT04109391"
"BiomarkerKG1193506727","RUCAPARIB, SACITUZUMAB GOVITECAN","ERBB2, ERS1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03992131"
"BiomarkerKG-563823741","PALBOCICLIB, LETROZOLE","ERBB2, ERS1, PGR, Ki67","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","TVV","clinicaltrials.gov","NCT04130152"
"BiomarkerKG1689293800","ATEZOLIZUMAB, G100","ERBB2, ERS1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03915678"
"BiomarkerKG1323565151","TREMELIMUMAB, DURVALUMAB","ERBB2, ERS1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03982173"
"BiomarkerKG3321966","CB-839, TALAZOPARIB","ERBB2, ERS1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03875313"
"BiomarkerKG1410798894","IPATASERTIB, FULVESTRANT, LETROZOLE, PALBOCICLIB","ERBB2, ERS1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED BREAST CANCER","TVV","clinicaltrials.gov","NCT03959891"
"BiomarkerKG-37577398","TAMOXIFEN CITRATE, LETROZOLE, EXEMESTANE","ERBB2, ERS1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","INVASIVE DUCTAL BREAST CANCER (STAGES I-III)","TVV","clinicaltrials.gov","NCT04129216"
"BiomarkerKG214156408","PERTUZUMAB, TRASTUZUMAB, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE, DOCETAXEL, CARBOPLATIN, PEGFILGRASTIM","ERBB2, ERS1, PGR","AND, AND/OR","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","LOCALLY ADVANCED BREAST CANCER","TVV","clinicaltrials.gov","NCT03329378"
"BiomarkerKG1059450097","DURVALUMAB, OLAPARIB, AZD6738","ERBB2, ERS1, PGR","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","INVASIVE TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03740893"
"BiomarkerKG-1378819185","NIVOLUMAB, NAB-PACLITAXEL, IPILIMUMAB","ERBB2, ERS1","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","TVV","clinicaltrials.gov","NCT04132817"
"BiomarkerKG-323468877","FUTIBATINIB, FULVERSTRANT","ERBB2, ERS1, PGR, FGFR2","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND FGFR2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","LOCALLY ADVANCED BREAST CANCER","TVV","clinicaltrials.gov","NCT04024436"
"BiomarkerKG-1064188360","FUTIBATINIB","ERBB2, ERS1, PGR, FGFR2","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE AND FGFR2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","LOCALLY ADVANCED BREAST CANCER","TVV","clinicaltrials.gov","NCT04024436"
"BiomarkerKG-1254885361","FUTIBATINIB, FULVERSTRANT","ERBB2, ERS1, PGR, FGFR1","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND FGFR1 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","LOCALLY ADVANCED BREAST CANCER","TVV","clinicaltrials.gov","NCT04024436"
"BiomarkerKG-1702088471","GEDATOLISIB, TALAZOPARIB","ERBB2, ERS1, PGR, BRCA1, BRCA2","AND, AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","UNRESECTABLE TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03911973"
"BiomarkerKG535034914","GEDATOLISIB, TALAZOPARIB","ERBB2, BRCA1, BRCA2","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","UNRESECTABLE TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03911973"
"BiomarkerKG716117938","NAB-PACLITAXEL, CARBOPLATIN, HERCEPTIN","ERBB2",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","BREAST CANCER","TVV","clinicaltrials.gov","NCT03907800"
"BiomarkerKG107230865","NAB-PACLITAXEL, CARBOPLATIN, HERCEPTIN","ERBB2, BRCA1, BRCA2","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 PROTEIN EXPRESSION NEGATIVE AND BRCA2 PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","TVV","clinicaltrials.gov","NCT03907800"
"BiomarkerKG2139946516","CYCLOPHOSPHAMIDE, CYTOKINE-BASED BIOLOGIC AGENT IRX-2, NIVOLUMAB","Absent",NA,"ABSENT NA NA","RECURRENT OR METASTATIC HEPATOCELLULAR CARCINOMA","ALV","clinicaltrials.gov","NCT03655002"
"BiomarkerKG-1142743362","ANLOTINIB HYDROCHLORIDE","Absent",NA,"ABSENT NA NA","ADVANCED HEPATOCELLULAR CARCINOMA","ALV","clinicaltrials.gov","NCT04213118"
"BiomarkerKG2027096547","COLCHICINE","AFP",NA,"AFP PROTEIN EXPRESSION POSITIVE","HEPATOCELLULAR CARCINOMA (IIIB-IV)","ALV","clinicaltrials.gov","NCT04264260"
"BiomarkerKG683286200","PRAVASTATIN","AFP",NA,"AFP PROTEIN EXPRESSION POSITIVE/NEGATIVE","HEPATOCELLULAR CARCINOMA","ALV","clinicaltrials.gov","NCT03219372"
"BiomarkerKG440468617","APATINIB","VEGF, AFP","AND","VEGF PROTEIN EXPRESSION POSITIVE AND AFP PROTEIN EXPRESSION POSITIVE","HEPATOCELLULAR CARCINOMA","ALV","clinicaltrials.gov","NCT03511703"
"BiomarkerKG329189688","ATG-008","HBV",NA,"HBV MISSING POSITIVE","ADVANCED UNRESECTABLE HEPATOCELLULAR CARCINOMA","ALV","clinicaltrials.gov","NCT03591965"
"BiomarkerKG1352760165","DERAZANTINIB","FGFR2",NA,"FGFR2 MUTATION/GENE FUSION/AMPLIFICATION POSITIVE","LOCALLY ADVANCED UNRESECTABLE OR METASTATIC COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA, LOCALLY ADVANCED UNRESECTABLE OR METASTATIC INTRAHEPATIC CHOLANGIOCARCINOMA","ALV","clinicaltrials.gov","NCT03230318"
"BiomarkerKG1751026797","RAMUCIRUMAB, MEDI4736","AFP",NA,"AFP PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA","ALV","clinicaltrials.gov","NCT02572687"
"BiomarkerKG-1685288106","SORAFENIB","AFP",NA,"AFP PROTEIN EXPRESSION POSITIVE","HEPATOCELLULAR CARCINOMA","ALV","clinicaltrials.gov","NCT03178656"
"BiomarkerKG626426273","BAVITUXIMAB, SORAFENIB","AFP",NA,"AFP PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARINOMA","ALV","clinicaltrials.gov","NCT01264705"
"BiomarkerKG-1504368928","PD-0332991","RB",NA,"RB PROTEIN EXPRESSION POSITIVE","ADVANCED HEPATOCELLULAR CARCINOMA","ALV","clinicaltrials.gov","NCT01356628"
"BiomarkerKG-1815733615","LENALIDOMIDE","Absent",NA,"ABSENT NA NA","ADVANCED HEPATOCELLULAR CARCINOMA","ALV","clinicaltrials.gov","NCT01545804"
"BiomarkerKG-61478009","BEVACIZUMAB, ERLOTINIB","Absent",NA,"ABSENT NA NA","ADVANCED LIVER CANCER","ALV","clinicaltrials.gov","NCT01180959"
"BiomarkerKG1400964458","AXITINIB","Absent",NA,"ABSENT NA NA","METASTATIC HEPATOCELLULAR CARCINOMA","ALV","clinicaltrials.gov","NCT01334112"
"BiomarkerKG936726893","EVEROLIMUS, PASIREOTIDE","AFP",NA,"AFP PROTEIN EXPRESSION POSITIVE","ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA","ALV","clinicaltrials.gov","NCT01488487"
"BiomarkerKG-595661003","SORAFENIB, E7050","Absent",NA,"ABSENT NA NA","UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HCC","ALV","clinicaltrials.gov","NCT01271504"
"BiomarkerKG-1250742185","ADI-PEG 20","Absent",NA,"ABSENT NA NA","ADVANCED HEPATOCELLULAR CARCINOMA","ALV","clinicaltrials.gov","NCT01287585"
"BiomarkerKG223828977","TYROSERLEUTIDE, MITOMYCIN, FLUOROURACIL","Absent",NA,"ABSENT NA NA","HEPATOCELLULAR CARCINOMA","ALV","clinicaltrials.gov","NCT01489566"
"BiomarkerKG-1086386656","TS-1, OXALIPLATIN","Absent",NA,"ABSENT NA NA","ADVANCED HEPATOCELLULAR CARCINOMA","ALV","clinicaltrials.gov","NCT01429961"
"BiomarkerKG-1960843667","S-1, LEUCOVORIN","Absent",NA,"ABSENT NA NA","ADVANCED HEPATOCELLULAR CARCINOMA","ALV","clinicaltrials.gov","NCT01533324"
"BiomarkerKG912675784","ETHIODIZED OIL, DOXORUBICIN","Absent",NA,"ABSENT NA NA","HEPATOCELLULAR CARCINOMA","ALV","clinicaltrials.gov","NCT01966133"
"BiomarkerKG-1583497180","PRAVASTATIN, SORAFENIB","Absent",NA,"ABSENT NA NA","ADVANCED HEPATOCARCINOMA","ALV","clinicaltrials.gov","NCT01418729"
"BiomarkerKG1436097858","SORAFENIB TOSYLATE, VORINOSTAT","AFP",NA,"AFP PROTEIN EXPRESSION POSITIVE","ADVANCED HEPATOCELLULAR CARCINOMA","TVV","clinicaltrials.gov","NCT01075113"
"BiomarkerKG1088441413","ASLAN001","HER3",NA,"HER3 PROTEIN EXPRESSION POSITIVE","METASTATIC HEPATOCELLULAR CARCINOMA","TVV","clinicaltrials.gov","NCT03499626"
"BiomarkerKG76141553","APATINIB, SHR-1210","AFP",NA,"AFP PROTEIN EXPRESSION NEAGATIVE","HEPATOCELLULAR CARCINOMA","TVV","clinicaltrials.gov","NCT03722875"
"BiomarkerKG-2114961874","RAMUCIRUMAB","AFP",NA,"AFP PROTEIN EXPRESSION POSITIVE","HEPATOCELLULAR CARCINOMA","TVV","clinicaltrials.gov","NCT02435433"
"BiomarkerKG1273878690","GALUNISERTIB, NIVOLUMAB","AFP",NA,"AFP PROTEIN EXPRESSION POSITIVE","RECURRENT HEPATOCELLULAR CARCINOMA","TVV","clinicaltrials.gov","NCT02423343"
"BiomarkerKG901214447","FISOGATINIB","FGF19",NA,"FGF19 PROTEIN EXPRESSION POSITIVE/NEGATIVE","HEPATOCELLULAR CARCINOMA","TVV","clinicaltrials.gov","NCT02508467"
"BiomarkerKG320452314","ERDAFITINIB","FGF19",NA,"FGF19 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","ADVANCED HEPATOCELLULAR CARCINOMA","TVV","clinicaltrials.gov","NCT02421185"
"BiomarkerKG-1047036954","OXALIPLATIN, 5-FLUOROURACIL","AFP",NA,"AFP PROTEIN EXPRESSION POSITVE/NEGATIVE","EARLY STAGE HEPATOCELLULAR CARCINOMA","TVV","clinicaltrials.gov","NCT02767375"
"BiomarkerKG1160551452","APATINIB","AFP",NA,"AFP PROTEIN EXPRESSION POSITIVE/NEGATIVE","ADVANCED HEPATOCELLULAR CANCER","TVV","clinicaltrials.gov","NCT03046979"
"BiomarkerKG1309435194","PEMBROLIZUMAB","AFP",NA,"AFP PROTEIN EXPRESSION POSITIVE/NEGATIVE","ADVANCED HEPATOCELLULAR CANCER","TVV","clinicaltrials.gov","NCT02658019"
"BiomarkerKG286515678","BEVACIZUMAB","
VEGF-A
",NA,"VEGF-A PROTEIN EXPRESSION NA","BREAST CANCER","Ben","PubMed","31564802"
"BiomarkerKG1449458760",NA,"miRNA",NA,"MIRNA GENE EXPRESSION NA","BREAST CANCER","Ben","PubMed","31549595"
"BiomarkerKG-338123991","CABOZANTINIB, TRASTUZUMAB","VEGFR 2",NA,"VEGFR 2 PROTEIN EXPRESSION NA","BREAST CANCER BRAIN METASTASES (BCBM)","Ben","PubMed","31541381"
"BiomarkerKG-1006830416",NA,"PIK3CA",NA,"PIK3CA MUTATION NA","BREAST CANCER PRECLINICAL MODELS.","Ben","PubMed","31534012"
"BiomarkerKG91698316",NA,"
SNP",NA,"SNP POLYMORPHISM NA","BREAST CANCER","Ben","PubMed","31519601"
"BiomarkerKG869601495",NA,"SLCO1B3",NA,"SLCO1B3 MUTATION NA","BREAST CANCER","Ben","PubMed","31434449"
"BiomarkerKG-1299119812",NA,"PD-1",NA,"PD-1 PROTEIN EXPRESSION NA","BREAST CANCER","Ben","PubMed","31357142"
"BiomarkerKG-1256644265","BAY 1125976","AKT",NA,"AKT MUTATION POSITIVE","BREAST CANCER","Ben","PubMed","31835495"
"BiomarkerKG-2145370017","NAPABUCASIN, TAMOXIFEN","ESR1",NA,"ESR1 PROTEIN EXPRESSION POSITIVE","ESTROGEN RECEPTOR-POSITIVE (ER+) BREAST CANCER","Ben","PubMed","31760402"
